Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
0.9493
+0.0993 (11.68%)
At close: May 19, 2025, 4:00 PM
0.8825
-0.0668 (-7.04%)
Pre-market: May 20, 2025, 8:09 AM EDT
Quince Therapeutics Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Quince Therapeutics stock ranges from a low of $4.00 to a high of $11. The average analyst price target of $8.00 forecasts a 742.73% increase in the stock price over the next year.
Price Target: $8.00 (+742.73%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 25, 2025.
Analyst Ratings
The average analyst rating for Quince Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 → $4 | Strong Buy | Maintains | $12 → $4 | +321.36% | Mar 25, 2025 |
Oppenheimer | Oppenheimer | Buy Initiates $10 | Buy | Initiates | $10 | +953.41% | Mar 24, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +1,164.09% | Feb 5, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +1,164.09% | Jan 2, 2025 |
Brookline Capital | Brookline Capital | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +848.07% | Dec 18, 2024 |
Financial Forecast
Revenue This Year
n/a
from 228.68M
Revenue Next Year
n/a
EPS This Year
-0.87
from -1.31
EPS Next Year
-0.73
from -0.87
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | 53.7M | ||
Avg | n/a | n/a | 30.0M | ||
Low | n/a | n/a | 17.7M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.64 | -0.12 | 0.24 | ||
Avg | -0.87 | -0.73 | -0.40 | ||
Low | -1.03 | -1.03 | -0.92 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.